Wilson Sonsini Goodrich & Rosati advised SR One, Norwest Venture Partners, and Delos Capital on the transaction. Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced an...
You must be a Standard 1 Year member to access this content.
Kirkland & Ellis advised SR One on the deal. SR One announced the close of its second fund at over $600 million, substantially exceeding its target of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini represented lead investors SR One and Norwest in the transaction. Rezo Therapeutics, a biotechnology company pioneering the integrated mapping of disease networks for precision...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SR One Capital Management on the deal. ADARx Pharmaceuticals, Inc., a biotechnology company developing RNA targeting therapeutics, announced the completion...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better...
You must be a Standard 1 Year member to access this content.
